

1 **Single versus Combination Treatment in Tinnitus: An** 2 **International, Multicentre, Parallel-arm, Superiority,** 3 **Randomised Controlled Trial**

4 Stefan Schoisswohl, Ph.D.^{1,2}, Laura Basso, Ph.D.¹, Jorge Simoes, Ph.D.³, Milena Engelke,
5 M.Sc.¹, Berthold Langguth, M.D.¹, Birgit Mazurek, M.D., Ph.D.⁴, Jose Antonio Lopez-
6 Escamez, M.D., Ph.D.^{5,6,7,8}, Dimitrios Kikidis, M.D., Ph.D.⁹, Rilana Cima, Ph.D.¹⁰, Alberto
7 Bernal-Robledano, M.Sc.^{5,6,7}, Benjamin Boecking, Ph.D.⁴, Jan Bulla, Ph.D.^{1,11}, Christopher
8 R. Cederroth, Ph.D.^{12, 13}, Holger Crump, Dipl.-Soz.-Wiss.¹⁴, Sam Denys, Ph.D.^{15,16}, Alba
9 Escalera-Balsera, M.Sc.^{5,6,7}, Alvaro Gallego-Martinez, Ph.D.^{5,6,7}, Silvano Gallus, Ph.D.¹⁷,
10 Hazel Goedhart, M.Sc.¹⁸, Leyre Hidalgo-Lopez, M.D.¹⁹, Carlotta M. Jarach, M.Sc.¹⁷, Hafez
11 Kader, M.Sc.²⁰, Michael Koller, Ph.D.²¹, Alessandra Lugo, Ph.D.¹⁷, Steven C. Marcum,
12 Ph.D.²², Nikos Markatos, B.Sc. (Honors)²³, Juan Martin-Lagos, M.D.^{5,6,24}, Marta Martinez-
13 Martinez, M.D., Ph.D.^{5,6,24}, Nicolas Muller-Locatelli, M.D.²⁴, Patrick Neff, Ph.D.^{1,25,26,27},
14 Uli Niemann, Dr. Ing.²⁰, Patricia Perez-Carpena, M.D., Ph.D.^{5,6,7,28}, Rüdiger Pryss, Ph.D.²⁹,
15 Clara Puga, M.Sc.²⁰, Paula Robles-Bolivar, M.Sc.^{5,6,7}, Matthias Rose, Ph.D.³⁰, Martin
16 Schecklmann, Ph.D.¹, Tabea Schiele, M.Sc.⁴, Miro Schleicher, M.Sc.²⁰, Johannes Schobel,
17 Ph.D.³¹, Myra Spiliopoulou, Dr. habil.²⁰, Sabine Stark, Dipl.-Psych.⁴, Susanne Staudinger,
18 M.A.¹, Alexandra Stege, Ph.D.³², Beat Toedtli, Ph.D.³³, Ilias Trochidis, M.Sc.³⁴, Vishnu
19 Unnikrishnan, M.Sc.²⁰, Evgenia Vassou, M.Sc.²³, Nicolas Verhaert, M.D. Ph.D.^{15,16}, Carsten
20 Vogel, M.Sc.²⁹, Zoi Zachou, M.D.²³ and Winfried Schlee, Ph.D.^{1,33}

21

22 ¹ Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

23 ² Department of Human Sciences, Institute of Psychology, Universitaet der Bundeswehr München, Neubiberg,
24 Germany

25 ³ Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands

26 ⁴ Tinnitus Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
27 Humboldt-Universität zu Berlin, and Berlin Institute of Health

28 ⁵ Otolology & Neurotology Group CTS495, Department of Genomic Medicine, GENYO. Centre for Genomics
29 and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Granada, Spain

30 ⁶ Instituto de Investigación Biosanitaria, ibs.GRANADA, Universidad de Granada, Granada, Spain

31 ⁷ Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en Enfermedades Raras,
32 CIBERER, 28029 Madrid, Spain

33 ⁸ Meniere's Disease Neuroscience Research Program, Faculty of Medicine & Health, School of Medical
34 Sciences, The Kolling Institute, University of Sydney, Sydney, New South Wales, Australia

35 ⁹ First Department of Otorhinolaryngology, Head and Neck Surgery, National and Kapodistrian University of
36 Athens, Hippocrateion General Hospital, Athens, Greece.

37 ¹⁰ Department of Health Psychology, Katholieke Universiteit Leuven, Leuven, Belgium.

38 ¹¹ Department of Mathematics, University of Bergen, 5020 Bergen, Norway

39 ¹² Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

40 ¹³ Translational Hearing Research, Tuebingen Hearing Research Center, Department of Otolaryngology, Head
41 and Neck Surgery, University of Tuebingen, Tuebingen, Germany

42 ¹⁴ Patient Organisation "Hast Du Toene – Leben mit Tinnitus" Bergisch-Gladbach, Bergisch-Gladbach, Germany

43 ¹⁵ Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Leuven, Katholieke
44 Universiteit Leuven, Leuven, Belgium

45 ¹⁶ Department of Neurosciences, Research Group Experimental Otorhinolaryngology (ExpORL), Katholieke
46 Universiteit Leuven, Leuven, Belgium

47 ¹⁷ Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

48 ¹⁸ Tinnitus Hub, London, United Kingdom

49 ¹⁹ Department of Mental Health, Hospital Universitario Virgen de las Nieves, Granada, ES, Spain.

50 ²⁰ Faculty of Computer Science, Otto-von-Guericke Universitaet Magdeburg, Germany

51 ²¹ Center for Clinical Studies, University of Regensburg, Regensburg, Germany

52 ²² Ear, Nose, Throat Department, University Hospital Regensburg, Regensburg, Germany

53 ²³ First Department of Otorhinolaryngology, Head and Neck Surgery, National and Kapodistrian University of
54 Athens, Hippocrateion General Hospital, Athens, Greece.

55 ²⁴ Department of Otolaryngology, Hospital Clinico Universitario San Cecilio, Granada, Spain

56 ²⁵ Department of Otorhinolaryngology, Head&Neck Surgery, University Hospital Zurich, University of Zurich,
57 Switzerland

58 ²⁶ Neuro-X Institute, École Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland

59 ²⁷ Centre for Cognitive Neuroscience, University of Salzburg, Salzburg, Austria

60 ²⁸ Department of Otolaryngology, Hospital Universitario Virgen de las Nieves, Granada, Spain

61 ²⁹ Institute of Clinical Epidemiology and Biometry University of Würzburg, Germany

62 ³⁰ Department of Internal Medicine and Psychosomatics, Charité – Universitätsmedizin Berlin, corporate
63 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

64 ³¹ Institute DigiHealth, Neu-Ulm University of Applied Sciences, Neu-Ulm, Germany

65 ³² Centrale Biobank Charité (ZeBanC), Charité – Universitätsmedizin Berlin, corporate member of Freie
66 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

67 ³³ Institute for Information and Process Management, Eastern Switzerland University of Applied Sciences, St.
68 Gallen, Switzerland

69 ³⁴ ViLabs, Limassol 3030, Cyprus

70

71 **Corresponding author:**

72 Stefan Schoisswohl, Ph.D.

73 Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg,
74 Germany

75 Stefan.schoisswohl@ukr.de

76 0049 941 941 2096

77 **Abstract**

78 Tinnitus is associated with a variety of aetiologies, phenotypes, and underlying
79 pathophysiological mechanisms, and available treatments have limited efficacy. A
80 combination of treatments, addressing various aspects of tinnitus, might provide a viable and
81 superior treatment strategy.

82 In this international multicentre, parallel-arm, superiority, randomised controlled trial, patients
83 with chronic subjective tinnitus were recruited from five clinical sites across the EU as part of
84 the interdisciplinary collaborative UNITI project. Patients were randomly assigned using a
85 web-based system, stratified by their hearing and distress level, to single or combination
86 treatment of 12 weeks. Cognitive-behavioural therapy, hearing aids, structured counselling,
87 and sound therapy were administered either alone or as a combination of two treatments
88 resulting in ten treatment arms. The primary outcome was the difference in the change from
89 baseline to week 12 in the total score of the Tinnitus Handicap Inventory (THI) between
90 single and combination treatments in the intention-to-treat population. All statistical analysis
91 were performed blinded to treatment allocation.

92 674 patients of both sexes aged between 18 and 80 years were screened for eligibility. 461
93 participants (190 females) with chronic subjective tinnitus and at least mild tinnitus handicap
94 were enrolled, 230 of which were randomly assigned to single and 231 to combination
95 treatment. Least-squares mean changes from baseline to week 12 were -11.7 for single
96 treatment (95% confidence interval [CI], -14.4 to -9.0) and -14.9 for combination treatments
97 (95% CI, -17.7 to -12.1), with a statistically significant group difference ($p=0.034$).
98 Cognitive-behavioural therapy and hearing aids alone had large effect sizes, which could not
99 be further increased by combination treatment. No serious adverse events occurred.

100 In this trial involving patients with chronic tinnitus, all treatment arms showed improvement
101 in THI scores from baseline to week 12. Combination treatments showed a stronger clinical
102 effect than single treatment, however, no clear synergistic effect was observed when
103 combining treatments. We observed rather a compensatory effect, where a more effective
104 treatment offsets the clinical effects of a less effective treatment.

105 ClinicalTrials.gov Identifier: NCT04663828.

106

107

108 **Main**

109 Tinnitus is defined as “the conscious awareness of a tonal or composite noise for which there
110 is no identifiable external acoustic source”,¹ with an estimated prevalence of 14.4% (95%
111 confidence interval [CI], 12.6 to 16.5) in the global population, with 2.3% (95% CI, 1.7 to
112 3.1) being severely affected.² Severe tinnitus is associated with emotional stress, cognitive
113 dysfunction, and/or autonomic arousal, leading to maladaptive behavioural changes and
114 functional disability.¹

115 Numerous causes and risk factors for tinnitus have been identified,³ whereby peripheral and
116 central mechanisms are involved in its emergence and maintenance, exemplified by
117 pathological alterations in the ear, along the auditory pathway⁴, as well as in non-auditory
118 brain regions.⁵ There is a broad spectrum of aetiologies, phenotypes, and underlying
119 pathophysiological mechanisms of tinnitus. Many adults with chronic tinnitus report having
120 tried multiple tinnitus treatments before finding a treatment that reduces their tinnitus
121 distress.⁶ Despite the availability of treatment guidelines,^{7,8} clear guidance on which treatment
122 strategy is best for the individual patient is not yet available. A viable option for clinical
123 management could be the combination of different treatment options to target various facets
124 of this symptom simultaneously.

125 However, studies on the efficacy of combining clinical interventions are scarce.⁹⁻¹¹ A
126 prominent example of combining different treatment types is represented by the combination
127 of a specific acoustic therapy with directive counselling termed Tinnitus Retraining
128 Therapy.¹²

129 The primary objective of the current trial was to compare the effect of single against
130 combination treatments for patients with chronic tinnitus. Four established treatment
131 strategies were selected: cognitive-behavioural therapy (CBT), hearing aids (HA), structured
132 counselling (SC), and sound therapy (ST).¹³ Participants were randomised either to a single
133 treatment out of this set of treatments or to a combination of two treatments. Further, we

134 attempt to overcome methodological weaknesses¹⁴ of previous trials by investigating a large
135 multinational sample of tinnitus patients, using harmonised patient selection and screening
136 procedures, as well as standardised interventions and assessments.

137

138 **Methods**

139 **Study design**

140 This was an investigator-initiated, international, multicentre, parallel-arm, superiority,
141 randomised controlled clinical trial conducted in five hospitals across four European countries
142 (Belgium, Germany, Greece, and Spain; see **Table S1** in the Supplementary Appendix) as
143 part of the UNITI project (Unification of Treatments and Interventions for Tinnitus
144 Patients).¹⁵ Included patients received treatment between April 2021 and December 2022.
145 Detailed information about the trial rationale, design, methodological approaches, and
146 statistical analysis strategies are published in the study protocol and statistical analysis plan
147 (SAP).^{16,17} The study was approved by local ethics committees at every clinical site
148 independently. Further, all authors vouch for the completeness and correctness of the data,
149 adherence of the trial to the study protocol,¹⁶ as well as adherence of data analysis strategies
150 to the SAP.¹⁷ A detailed list of author contributions can be found in the Supplementary
151 Appendix. Written informed consent was obtained from all eligible patients prior to trial
152 participation. For the preparation of this report we used the CONSORT guidelines
153 (Consolidated Standards of Reporting Trials).¹⁸

154

155 **Participants**

156 Adults of both sexes (self-reported) aged between 18 and 80 years with chronic subjective
157 tinnitus (lasting for six months or more) were recruited and screened at each clinical site.
158 Inclusion criteria for trial participation were at least mild tinnitus handicap according to the
159 Tinnitus Handicap Inventory¹⁹ (THI; score \geq 18) and tinnitus as primary complaint. Exclusion

160 criteria were: presence of a mild cognitive impairment according to the Montreal Cognitive
161 Assessment²⁰ (MoCa; score ≤ 22); any relevant ear disorders or acute infections of the ear;
162 one deaf ear; severe hearing loss (inability to communicate properly) as well as serious
163 internal, neurological, or psychiatric conditions. Existing drug therapies with psychoactive
164 substances had to be stable, and no start of any other tinnitus-related treatment in the last three
165 months before trial participation was allowed. A detailed list of all eligibility criteria can be
166 found in the trial protocol.¹⁶ Written informed consent was obtained from all participants.

167

168 **Randomisation and blinding**

169 After successful on-site screening, eligible participants were stratified in four equally sized
170 strata based on their THI total score (low [< 48] and high [≥ 48] tinnitus-related handicap) and
171 hearing aid indication (yes and no, criteria for hearing aid indication: **Table S2**). Participants
172 were then randomised to one of ten treatment arms comprised of single (CBT, HA, SC, ST)
173 and combination interventions (CBT+HA, CBT+SC, CBT+ST, HA+SC, HA+ST, SC+ST).
174 Patients from the two strata without hearing aid indication were not randomised in treatment
175 groups that comprised HA treatment. Randomisation was conducted at each clinical site with
176 an interactive web response system developed together with biostatisticians from the contract
177 research organization Excelya (www.excelya.com). Excelya was further responsible to
178 monitor all randomisation proceedings. Treatment codes were used to assure blindness of the
179 statistical analysis team to the type of treatment patients received. Unblinding was conducted
180 after analyses completion. See study protocol and statistical analysis plan for more detailed
181 information.^{16,17}

182

183 **Procedures**

184 Single and combination treatments were applied over a 12-week treatment phase. CBT was
185 based on the concept of fear-avoidance using exposure therapy²¹ and delivered by trained

186 psychologists or psychotherapists in weekly face-to-face group sessions (1.5-2 hours; group
187 size: six to eight participants). For HA treatment, behind-the-ear hearing instruments (Type
188 Signia Pure 312 7X; Sivantos Pte. Ltd., Singapore, Republic of Singapore/ WSAudiology,
189 Lyngø, Denmark) were fitted bilaterally with all noise-related signal processing deactivated
190 by audiologists or HA acousticians according to the National Acoustic Laboratories-Non-
191 Linear 2 generic amplification proceeding.²² SC and ST were self-administered on a daily
192 basis via dedicated mobile applications.²³ SC consisted of 12 chapters featuring structured
193 patient education and tips on how to handle tinnitus distress. ST included a set of various
194 artificial and naturalistic sounds. All treatment procedures were designed by dedicated experts
195 in their respective fields (see **Table S3**) and described in detail in the study protocol.¹⁶
196 Demographic and clinical characteristics were assessed at baseline (before treatment) using
197 the European School of Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-
198 SQ).²⁴ Outcome measures were assessed at baseline, interim (after 6 weeks of treatment),
199 final (after 12-week treatment period), and follow-up (36 weeks after baseline) visits. An
200 additional follow-up visit (48 weeks after baseline) was conducted on a voluntary basis. Due
201 to its voluntary nature and the associated large amount of missing data, this additional follow-
202 up was not included in the final outcome measure analysis.

203

204 **Outcome measures**

205 The primary outcome was the difference in change from baseline to final visit (after 12 weeks
206 of treatment) in the Tinnitus Handicap Inventory (THI),¹⁹ which consists of 25 items to
207 quantify tinnitus handicap (total scores range: 0-100), between single and combination
208 treatment. Changes from baseline to interim visit, and follow-up were examined in secondary
209 analyses as well. Secondary outcome measures included the Tinnitus Functional Index
210 (TFI),²⁵ the Mini Tinnitus Questionnaire (Mini-TQ),²⁶ the Patient Health Questionnaire for
211 Depression (PHQ-D/PHQ-9),²⁷ the abbreviated version of the World Health Organisation -

212 Quality of Life questionnaire (WHO-QoL)²⁸ as well as numeric rating scales (NRS) for
213 tinnitus impairment, tinnitus loudness, tinnitus-related discomfort, annoyance, unpleasantness,
214 and ability to ignore the tinnitus.²⁹ Clinical improvement was measured with the Clinical
215 Global Impression Scale – Improvement (CGI-I).³⁰
216 Adverse (AE) and serious adverse events (SAE) were defined according to the guidelines for
217 Good Clinical Practice §3 (6,8). AEs were assessed and recorded during each visit with
218 respect to start and end date, intensity, relation to intervention, impact on treatment, and
219 actions taken. Any SAE during the 12-week treatment phase led to a stop of the patient’s
220 respective treatment and was immediately reported to the local ethics committee.

221

222 **Statistical Analysis**

223 The sample size was determined a priori on an estimated effect size of 0.26, an alpha level of
224 5% and a power of 80% (two-sided test). Based on that, the necessary sample size is 468.
225 Considering potential dropouts, the aim was to recruit a total sample size of N = 500.¹⁶
226 The statistical analysis was performed in the intention-to-treat (ITT) population of N = 461,
227 including all randomised participants, regardless of compliance with the study protocol. For
228 the primary analysis (combination against single treatments), we estimated that with a two-
229 tailed alpha level of less than 0.05, the sample size of N = 461 provides the trial with 90%
230 power to detect an effect size of 0.30 (lower end of 95% CI for effect size of behavioural
231 therapy interventions according to the latest Cochrane Review on tinnitus).³¹
232 For the ITT analysis, missing values (THI: 18%, education: 3.5%, PHQ-9 baseline: 2.6%)
233 were imputed using multilevel imputation (R package `mitml`)^{32,33}; see **Figure S2** for the
234 distribution of imputed THI values. The missing at random assumption was checked as
235 described in the SAP and no indications of violation were found. As sensitivity analysis, a
236 per-protocol analysis was conducted on all patients who met the requirements for treatment


237 compliance as defined in the SAP (N = 185, **Table S32**).³⁴ An additional sensitivity analyses
238 was performed without imputation of the primary outcome (**Table S34**).

239 The analysis of the primary objective was performed in the ITT population to test the efficacy
240 of combination treatments against single treatments. Further comparisons between single
241 versus combination treatments for all 4 single treatments separately (CBT single vs.
242 combined, HA single vs. combined, SC single vs. combined, ST single vs. combined) as well
243 as comparisons between all ten treatment arms were performed.^{16,34} To address all objectives,
244 mixed effect models were applied (with REML using the `lme4` R package)³⁵ by considering
245 the outcome as the response variable and including the corresponding objective, time point
246 (baseline, interim visit, final visit, and follow-up), and objective-by-time interaction as fixed
247 effects, including centre and subject ID as random intercepts. The models were adjusted for
248 the following covariates: age, sex, educational attainment, hearing aid indication, and PHQ-9
249 baseline scores.³⁴ The results of the remaining objectives as described in the SAP are reported
250 in the Supplementary Appendix.

251 Results are reported as least-squares mean changes (obtained via the `emmeans` R package)³⁶
252 with 95% confidence intervals. All analyses were performed in R (version 4.2.2).

253 De-identified data (pseudo-anonymised code) were gathered in a central database, which was
254 regularly monitored and systematically checked for missing and invalid data (every six
255 weeks). After database closure and prior to analysis, data from each clinical centre were
256 checked again for validity and completeness. This study was registered at ClinicalTrials.gov,
257 NCT04663828.

258



259

260 **Figure 1. Trial Profile**

261 A total of 674 patients were screened, of whom 461 met the trial inclusion criteria and were randomly assigned
 262 to one of ten treatment arms comprised of a single treatment or a combination of two treatments out of four
 263 different therapy approaches - cognitive-behavioural therapy (CBT), hearing aids (HA), structured counselling
 264 (SC), and sound therapy (ST). 230 (49.9%) were assigned to single treatments (CBT, HA, SC, or ST) and 231
 265 (50.1%) were assigned to combination treatments (CBT+HA, CBT+SC, CBT+ST, HA+SC, HA+ST, SC+ST).
 266 Patients without hearing aid indication were only randomised to treatments without HA. An extended version of
 267 the patient's flowchart can be found in **Figure S1**. Quantity and reasons for trial exclusion during eligibility
 268 assessments and trial discontinuation can be seen from **Tables S5 – S9**.

269 **Results**

270 Between Apr 16, 2021, and Sept 20, 2022, 674 persons with tinnitus were assessed for
271 eligibility, of whom 461 (68.3%) fulfilled the inclusion criteria and consented to participate.
272 After randomisation, 230 were allocated to single treatments and 231 were allocated to
273 combination treatments (**Figure 1**). The initial planned sample size for the trial was 500
274 patients.¹⁶ Since our study plan required a recruitment of an exact number of patients with
275 specific tinnitus profiles (eligibility criteria and stratification proceedings), plus the trial was
276 performed during the COVID-19 pandemic, recruitment and inclusion processes took us
277 significantly longer than expected. Hence, we closed the trial in December 2022 with N = 461
278 included and treated patients, in order to keep to the schedule of our funding period. A post
279 hoc power computation indicates that with a two-tailed alpha level of less than 5%, the
280 available sample size of N = 461 provides our trial with 79.5% power to detect an effect size
281 of 0.26.

282 **Table 1** shows the baseline characteristics by treatment arm. Mean baseline THI total scores
283 were 48.5 (SD 19.5) in the single treatment group and 47.4 (SD 19.9) in the combined
284 treatment group. Except for age and hearing aid indication, the baseline characteristics were
285 generally well balanced between the treatment arms (see **Table 1** and **Table S10**). Both age
286 and hearing aid indication were considered as covariates during statistical analyses. The
287 difference in hearing aid indication results from randomising only individuals with relevant
288 hearing loss to HA treatment arms. Results of audiometric measurements are shown in **Figure**
289 **S3** and **S4**. Participants' baseline characteristics were similar to the group of persons with
290 tinnitus seeking medical help in the general population (**Table S4**).

Table 1. Demographic and clinical characteristics of the participants at baseline (stratified by treatment arm).												
Characteristics	CBT (n=56)	HA (n=59)	SC (n=56)	ST (n=59)	CBT+HA (n=17)	CBT+SC (n=51)	CBT+ST (n=54)	HA+SC (n=19)	HA+ST (n=27)	SC+ST (n=63)	Overall (N=461)	
Demographic characteristics												
Sex												
Male (%)	34 (60.7%)	36 (61.0%)	39 (69.6%)	32 (54.2%)	12 (70.6%)	27 (52.9%)	33 (61.1%)	12 (63.2%)	18 (66.7%)	28 (44.4%)	271 (58.8%)	
Female (%)	22 (39.3%)	23 (39.0%)	17 (30.4%)	27 (45.8%)	5 (29.4%)	24 (47.1%)	21 (38.9%)	7 (36.8%)	9 (33.3%)	35 (55.6%)	190 (41.2%)	
Age (years)	48.8 ±12.3	53.4 ±11.7	49.8 ±13.1	50.3 ±14.0	56.0 ±10.4	54.0 ±12.0	46.4 ±12.9	51.6 ±14.0	55.0 ±11.2	51.2 ±9.8	51.1 ±12.4	
PHQ-9 total score	7.3 ±4.9	7.3 ±4.8	7.2 ±4.5	8.5 ±5.2	5.8 ±4.6	6.8 ±4.3	7.9 ±5.0	6.8 ±3.2	7.0 ±5.6	7.0 ±5.5	7.3 ±4.9	
Tinnitus characteristics												
Tinnitus duration (in months)	119 ±127	126 ±100	85 ±77	115 ±114	101 ±111	154 ±140	110 ±99	159 ±144	124 ±108	119 ±116	119 ±113	
Hearing aid indication (%)	19 (33.9%)	59 (100%)	19 (33.9%)	20 (33.9%)	17 (100%)	18 (35.3%)	17 (31.5%)	19 (100%)	27 (100%)	19 (30.2%)	234 (50.8%)	
THI total score	47.8 ±20.3	48.8 ±19.2	48.6 ±20.6	48.7 ±18.1	42.2 ±18.9	45.5 ±18.9	48.0 ±19.3	52.2 ±21.9	50.1 ±20.1	47.2 ±20.9	48.0 ±19.7	
TFI total score	47.8 ±21.4	50.6 ±18.8	48.5 ±20.7	50.9 ±18.1	46.1 ±18.9	42.9 ±18.8	47.4 ±22.7	51.7 ±21.3	54.5 ±21.4	48.1 ±20.9	48.6 ±20.3	
Mini-TQ total score	11.4 ±5.2	12.2 ±4.6	11.8 ±5.4	12.5 ±5.0	10.7 ±4.0	11.2 ±5.0	12.3 ±4.6	11.9 ±5.2	12.3 ±6.0	12.0 ±5.2	11.9 ±5.0	
Tinnitus loudness (rating)	6.2 ±2.1	6.7 ±1.7	6.4 ±2.4	6.3 ±2.1	6.3 ±2.7	6.0 ±2.6	6.2 ±2.6	6.4 ±2.3	7.2 ±1.6	6.3 ±2.2	6.4 ±2.2	

291 **Table 1. Demographic and Clinical Characteristics of the Participants at Baseline.**

292 Data are n (%) or mean \pm SD.

293 PHQ-9 scores range from 0 to 27, with higher scores indicating greater severity of depression.

294 The definition for hearing aid indication is given in Table S2.

295 THI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus.

296 TFI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus.

297 Mini-TQ scores range from 0 to 24, with higher scores indicating greater severity of tinnitus.

298 Tinnitus loudness (rating) scores range from 0 to 10, with higher scores indicating greater loudness of tinnitus.

299 Abbreviations: CBT = Cognitive-Behavioural Therapy; HA = Hearing Aids; PHQ-9 = Patient Health

300 Questionnaire for Depression; SC = Structured Counselling; ST = Sound Therapy; TFI = Tinnitus Functional

301 Index; THI = Tinnitus Handicap Inventory; TQ = Tinnitus Questionnaire.

302

303 Regarding the primary objective, the least-squares mean change from baseline to week 12 in

304 the THI total score was -11.7 (95% confidence interval [CI], -14.4 to -9.0) for the single

305 treatment groups and -14.9 (95% CI, -17.7 to -12.1) for the combination treatment arms (see

306 **Figure 2 & Table 2**) (interaction effect [single vs. combination treatments at final visit vs.

307 baseline] $\beta = 3.2$, 95% CI, 0.2 to 6.1, $p = 0.034$). Model parameters and model assumptions

308 for the primary objective can be found in **Table S12** and **Figure S5**. The least-squares mean

309 change from baseline to week 12 in the THI total score for the single vs. combination

310 treatment comparison for each treatment strategy is reported in **Table 2**, and separately for

311 every treatment arm in **Table 3** and **Figure S6**; and further separated by hearing aid indication

312 in **Table S13** and tinnitus severity in **Table S14**. **Figure 2** shows least-squares mean changes

313 from baseline to interim visit at week 6, final visit at week 12, and follow-up at week 36 for

314 both the overall and individual single-combination treatment comparison. The results of the

315 remaining objectives (as outlined in the SAP)¹⁷ and time points (interim visit and follow up)

316 are reported in **Tables S16 – S18**.

317 Regarding the secondary outcome measures, least-squares mean change from baseline to

318 week 12 for TFI, Mini-TQ, PHQ-9, WHO-QoL, and NRS (all objectives) are shown in


319 **Tables 2** and **3** as well as **Tables S19 – S31**. Results of CGI-I are reported descriptively for

320 single and combination treatment groups at final visit, see **Figure S7 & S8**, and separated by
321 hearing aid indication (**Figure S9**) and tinnitus severity (**Figure S10**).

322 No serious adverse event was evident in any participant. Adverse events appeared in 49
323 (21.3%) participants in single treatment groups, and in 49 (21.2%) participants in combination
324 treatment groups. A full listing of all adverse events is provided in **Table S11**. Information on
325 treatment adherence is given in **Figure S1**.

326 Pairwise post-hoc contrasts for the THI least-squares mean change revealed statistically
327 significant (Bonferroni adjusted) differences between ST and CBT, ST and CBT+SC, ST and
328 CBT+ST, ST and HA, and ST and HA+SC. For all other treatment contrasts, no statistically
329 significant differences were found (all p -values > 0.050). Statistical parameters for all post-
330 hoc contrasts are listed in **Table S15**. The intention-to-treat and the sensitivity analysis
331 yielded similar results (**Table S34**). Per-protocol findings were different for the overall single
332 vs. combination contrast (no statistical superiority of combination treatment; $\beta = 2.8$, 95% CI,
333 -1.6 to 7.2 , $p = 0.206$) (**Figure S11, Tables S32 – S33**). Exploratory analysis included the
334 effect size estimates Cohen's d for all treatment arms which are shown in **Table 3** and **Figure**
335 **2**.

336



337

338 **Figure 2. Least-Squares Mean Changes from Baseline to interim visit (6w), final visit (12w) and follow-up**
 339 **(36w) in THI total score. A) single and combination treatments; C) CBT+HA; D) CBT+SC; E) CBT+ST; F)**
 340 **HA+SC; G) HA+ST; H) SC+ST; and B) Cohen's d values for all treatment arms (change in THI total score from**
 341 **baseline to final visit). Total THI scores range from 0 to 100, with higher scores indicating greater severity of**
 342 **tinnitus. Error bars represent 95% confidence intervals. Abbreviations: CBT = Cognitive-Behavioural Therapy;**
 343 **HA = Hearing Aids; SC = Structured Counselling; ST = Sound Therapy; THI = Tinnitus Handicap Inventory.**

344

Table 2. Primary and Secondary Clinical Outcomes at Final Visit: Single vs. Combination (Intention-to-Treat Population).										
	All treatments		Cognitive Behavioural Therapy		Hearing Aid		Structured Counselling		Sound Therapy	
	Single	Combination	Single	Combination	Single	Combination	Single	Combination	Single	Combination
Primary outcome										
THI										
Change from baseline	-11.7	-14.9	-16.9	-15.6	-14.4	-15.7	-12.0	-15.5	-3.8	-13.2
(95% CI)	(-14.4 to -9.0)	(-17.7 to -12.1)	(-22.8 to -10.9)	(-19.5 to -11.7)	(-19.5 to -9.4)	(-20.7 to -10.7)	(-17.5 to -6.5)	(-19.3 to -11.7)	(-9.3 to 1.6)	(-16.7 to -9.8)
Secondary Outcome										
TFI										
Change from baseline	-11.0	-11.6	-16.1	-12.1	-14.5	-13.9	-9.7	-10.1	-3.7	-11.7
(95% CI)	(-13.9 to -8.0)	(-14.7 to -8.5)	(-22.1 to -10.1)	(-16.3 to -7.9)	(-20.2 to -8.9)	(-19.4 to -8.4)	(-15.5 to -3.9)	(-14.0 to -6.2)	(-9.6 to 2.1)	(-15.5 to -7.9)
Mini-TQ										
Change from baseline	-2.9	-3.4	-4.1	-3.8	-3.5	-3.0	-2.9	-3.4	-1.2	-3.0
(95% CI)	(-3.6 to -2.2)	(-4.1 to -2.7)	(-5.5 to -2.6)	(-4.8 to -2.8)	(-4.7 to -2.4)	(-4.2 to -1.9)	(-4.3 to -1.4)	(-4.3 to -2.5)	(-2.6 to 0.2)	(-3.9 to -2.2)
NRS-2										
Change from baseline	-0.8	-0.8	-0.5	-0.8	-1.4	-0.8	-0.8	-0.7	-0.3	-0.8
(95% CI)	(-1.2 to -0.4)	(-1.2 to -0.4)	(-1.4 to 0.3)	(-1.4 to -0.2)	(-2.2 to -0.6)	(-1.6 to -0.1)	(-1.6 to 0.0)	(-1.2 to -0.2)	(-1.0 to 0.5)	(-1.3 to -0.3)
PHQ-9										
Change from baseline	-1.7	-1.4	-1.7	-1.7	-2.3	-1.5	-1.7	-1.3	-0.8	-1.3
(95% CI)	(-2.3 to -1.0)	(-2.1 to -0.8)	(-3.0 to -0.3)	(-2.6 to -0.8)	(-3.5 to -1.2)	(-2.6 to -0.4)	(-3.1 to -0.4)	(-2.2 to -0.5)	(-2.2 to 0.6)	(-2.2 to -0.4)

345 **Table 2. Primary and Secondary Clinical Outcomes at Final Visit: Single vs. Combination (ITT).**
 346 Values depict least-squares mean changes at week 12 for primary and secondary outcomes with 95% confidence intervals.

Table 3. Primary and Secondary Clinical Outcomes at Final Visit: All Treatment Arms (Intention-to-Treat Population).

347 Higher total scores on the THI, TFI and Mini-TQ indicate greater severity of tinnitus.
348 Higher total scores on the NRS-2 indicate greater loudness of tinnitus.
349 Higher total scores on the PHQ-9 indicate greater severity of depression.
350 Further objectives and secondary clinical outcomes not reported in this table can be seen in the Supplementary Appendix.
351 Abbreviations: NRS = Numeric Rating Scale; PHQ-9 = Patient Health Questionnaire for Depression; TFI = Tinnitus Functional Index; THI = Tinnitus Handicap Inventory; TQ =
352 Tinnitus Questionnaire.
353
354

	CBT	HA	SC	ST	CBT+HA	CBT+SC	CBT+ST	HA+SC	HA+ST	SC+ST
Primary outcome										
THI										
Change from baseline	-16.9	-14.4	-12.0	-3.8	-15.2	-17.4	-14.1	-20.0	-12.9	-12.7
(95% CI)	(-22.7 to -11.0)	(-19.7 to -9.2)	(-17.5 to -6.5)	(-9.2 to 1.5)	(-26.0 to -4.4)	(-23.8 to -11.0)	(-19.8 to -8.4)	(-29.3 to -10.8)	(-20.5 to -5.3)	(-17.8 to -7.5)
Cohen's d (95% CI)	0.93 (0.70 to 1.21)	1.00 (0.78 to 1.28)	0.83 (0.51 to 1.27)	0.24 (-0.02 to 0.53)	1.13 (0.74 to 1.83)	1.19 (0.91 to 1.59)	0.80 (0.55 to 1.12)	1.35 (0.98 to 1.99)	0.78 (0.43 to 1.37)	0.71 (0.46 to 1.02)
Secondary Outcome										
TFI										
Change from baseline	-16.1	-14.5	-9.7	-3.7	-15.1	-10.9	-12.2	-10.1	-15.8	-9.4
(95% CI)	(-22.2 to -10.0)	(-20.1 to -8.9)	(-15.6 to -3.8)	(-9.5 to 2.0)	(-26.1 to -4.0)	(-17.4 to -4.4)	(-18.5 to -5.9)	(-20.0 to -0.2)	(-24.0 to -7.6)	(-15.1 to -3.8)
Mini-TQ										
Change from baseline	-4.1	-3.5	-2.9	-1.2	-4.0	-4.1	-3.6	-3.2	-2.3	-2.9
(95% CI)	(-5.5 to -2.6)	(-4.8 to -2.2)	(-4.3 to -1.4)	(-2.6 to 0.2)	(-6.7 to -1.3)	(-5.6 to -2.6)	(-5.0 to -2.2)	(-5.5 to -0.9)	(-4.3 to -0.4)	(-4.2 to -1.6)
NRS-2										
Change from baseline	-0.5	-1.4	-0.8	-0.3	-1.0	-0.9	-0.7	-0.3	-1.1	-0.7
(95% CI)	(-1.4 to 0.3)	(-2.1 to -0.6)	(-1.6 to 0.0)	(-1.1 to 0.5)	(-2.5 to 0.6)	(-1.8 to 0.0)	(-1.5 to 0.1)	(-1.6 to 1.1)	(-2.2 to -0.1)	(-1.5 to 0.0)
PHQ-9										
Change from baseline	-1.7	-2.3	-1.7	-0.9	-1.2	-1.8	-1.8	-2.0	-1.3	-0.8
(95% CI)	(-3.0 to -0.3)	(-3.6 to -1.1)	(-3.1 to -0.4)	(-2.2 to 0.4)	(-3.7 to 1.2)	(-3.2 to -0.3)	(-3.2 to -0.4)	(-4.2 to 0.2)	(-3.1 to 0.6)	(-2.1 to 0.4)

355 **Table 3. Primary and Secondary Clinical Outcomes at Final Visit: All treatment Arms (ITT).**
 356 Values depict least-squares mean changes at week 12 for primary and secondary outcomes with 95% confidence intervals.
 357 Higher total scores on the THI, TFI and Mini-TQ indicate greater severity of tinnitus.
 358 Higher total scores on the NRS-2 indicate greater loudness of tinnitus.
 359 Higher total scores on the PHQ-9 indicate greater severity of depression.

360 Cohens d indicate the standardised effect size of the respective treatment.
361 The effect sizes and the corresponding confidence intervals were first computed in each of the 50 imputed data sets before they were averaged to a single value.
362 Further objectives and secondary clinical outcomes not reported in this table can be seen in the Supplementary Appendix.
363 Abbreviations: CBT = Cognitive-Behavioural Therapy; HA = Hearing Aids; NRS = Numeric Rating Scale; PHQ-9 = Patient Health Questionnaire for Depression; SC =
364 Structured Counselling; ST = Sound Therapy; TFI = Tinnitus Functional Index; THI = Tinnitus Handicap Inventory; TQ = Tinnitus Questionnaire.
365

366 **Discussion**

367 In this randomised trial on chronic tinnitus, the efficacy of established tinnitus treatments
368 (CBT, HA, SC, and ST) applied either alone or as a combination of two treatments was
369 investigated. All treatments were safe and the improvement in THI scores from baseline to
370 week 12 was statistically stronger for combination compared to single treatment. However, a
371 more detailed analysis of our data by pairwise post hoc comparisons of the various treatment
372 arms suggests that the additional effect of a treatment combination depends on the efficacy of
373 a single treatment. In the case of ST, a clear superiority in favour of combination treatment
374 was present, with the combination CBT+ST being statistically more effective than single ST.
375 Importantly, there was no statistically significant difference between CBT alone and
376 CBT+ST. This finding shows that combining a treatment with low efficacy (in this case ST)
377 together with a treatment of high efficacy (in this case CBT) does not lead to a simple
378 regression to the mean.

379 Rather the high-efficacy treatment counterbalances the effect of the low-efficacy treatment
380 and elevates the clinical improvement up to a level comparable to the single high-efficacy
381 treatment. Together with the observation that ST was the treatment which demonstrated the
382 smallest improvements in tinnitus-related handicap (statistically significant less than CBT,
383 HA, CBT+SC, CBT+ST, HA+SC), the additional beneficial effect of a treatment combination
384 appears to depend on how effective a single treatment already performs. For the single
385 treatment arm with ST, we observed a weak effect size of 0.24 (CI, -0.02 to 0.53) while
386 combinations of treatments including ST yielded medium to strong effect sizes: SC+ST
387 (Cohen's $d = 0.71$, CI, 0.46 to 1.02), HA+ST (Cohen's $d = 0.78$, CI, 0.43 to 1.37), and
388 CBT+ST (Cohen's $d = 0.80$, CI, 0.55 to 1.12), which is driven by the combination treatments
389 of higher efficacy.

390 The weak clinical efficacy of sound treatment alone is in line with previous work where
391 sound treatment was used as an active comparator.³⁷ This trial shows that combining a

392 treatment of weak clinical efficacy with a treatment of stronger clinical efficacy
393 counterbalanced the weak effect and provokes a clinical improvement comparable to the
394 stronger effect. On the other hand, if a single treatment is already effective, a combination
395 might not result in a synergistic effect.

396 Previous investigations evaluated combination treatments for tinnitus as well.⁹⁻¹¹ For instance
397 it was demonstrated that Tinnitus Retraining Therapy,¹² which combines a specific acoustic
398 therapy with directive counselling, reduced tinnitus symptoms more effectively than
399 counselling alone.⁹

400 However, this is the first systematic trial to investigate CBT, HA, ST, and SC within the
401 scope of one investigation. With the present trial, we can directly put into perspective the
402 effect size of CBT as the most established treatment in tinnitus,^{7,8,31} with HA, ST, and SC (ST
403 and SC provided with mobile applications) as well as their combinations as treatment options
404 for tinnitus. The combination of HA+SC, which provided the strongest effect size in our trial,
405 has not been investigated so far, and data about the clinical efficacy in tinnitus are not yet
406 available.^{38,39}

407 For the interpretation of the results, it should be considered that we worked with a selected set
408 of four tinnitus treatments and combinations of two treatment types. Thus, it remains
409 unknown, whether the combination of other treatment sets or combinations of three or more
410 treatment types would lead to additional treatment benefits. The duration of treatment was 12
411 weeks in all treatment arms. Meaningful clinical improvements were observed in most
412 treatment arms after 6 weeks and improved further towards the final assessment after 12
413 weeks and remained during the follow-up period.

414 Despite the usage of interventions allowing for a high level of patient flexibility (SC and ST
415 via mobile applications, HA), treatment compliance/adherence was low (see **Table S35**) and
416 drop-out rates were high in our trial (PP sample of 185 patients). With the application of two
417 treatments in combination, the chances that one or even both treatments are not conducted as

418 intended are increasing. Further, high drop-out rates are a well-known issue in mobile health
419 interventions.⁴⁰ Another reason could be that patients were randomized to treatments and did
420 not receive the treatment they desired. Under ideal treatment compliance/adherence (PP
421 analysis), we observed no overall superiority of combination treatments.

422 A potential explanation for this incongruency between ITT and PP analysis might be that
423 under perfect conditions (PP), a single treatment which is conducted properly is already
424 effective on its own and thus there is no clear additional beneficial effect of a combination
425 treatment. However, if one or two treatments are not properly conducted (ITT), as it is most
426 probably the case in the everyday clinical treatment of tinnitus, a combination of treatments
427 provides an additional benefit. Our results indicate that there is a high need for further
428 research to better understand the clinical effects of combination treatment; to get more
429 profound insights behind the reasons for low treatment adherence; and in approaches to
430 increase treatment adherence in daily clinical practice, such as the implementation of
431 behavioral change techniques or more extensive patient education.

432 A placebo group was not included in this trial, as the answer to the main question
433 (comparison of single and combined treatment) did not require a placebo arm. Nevertheless, a
434 placebo group may have been helpful as an anchor for comparison with the ten treatment
435 arms. However, our results of CBT as single treatment correspond very well to meta-analytic
436 data of its efficacy³¹ and thus provide an anchor for a well-established evidence based
437 treatment approach. Further, our data demonstrates low efficacy of ST as a single treatment,
438 supporting its use as an active control condition in randomised controlled trials.⁴¹ Thus, the
439 two treatment arms CBT and ST can be considered as reliable reference anchors for the
440 interpretation of the results of the other 8 investigated treatment arms.

441 Even though in 18% of all participants data of the primary outcome was missing, the
442 sensitivity analysis (no imputation of THI) came to a similar finding regarding our primary
443 objective.

444

445 In this trial involving adults with chronic tinnitus, we found that 12 weeks of treatment with
446 CBT, HAs, SC, or ST applied as single or in combinations of two treatments led to an
447 amelioration in tinnitus-related handicap. There was no unambiguous synergistic effect of
448 treatment combination, rather a compensatory effect, where a more effective treatment offsets
449 the clinical effects of a less effective treatment. In clinical situations where it is unclear which
450 treatment will benefit the patient, a combination of treatments might help to increase the
451 chances of treatment success.

452

453 **Contributions**

454 Stefan Schoisswohl (SSch) contributed to conceptualisation, investigation, formal analysis,
455 methodology, project administration, supervision, visualisation, and writing – original draft;
456 Winfried Schlee (WS) contributed to conceptualisation, funding acquisition, formal analysis,
457 methodology, project administration, supervision, visualisation, and writing – original draft;
458 Berthold Langguth (BL) contributed to conceptualisation, funding acquisition, methodology,
459 supervision, and writing – review & editing; Laura Basso (LB) and Milena Engelke (ME)
460 contributed to data curation, formal analysis, methodology, visualisation, and writing –
461 original draft; Rüdiger Pryss (RP) contributed to funding acquisition, investigation,
462 methodology, software, and writing – review & editing; Birgit Mazurek (BM), Jose Antonio
463 Lopez-Escamez (JALE), Dimitrios Kikidis (DK), and Rilana Cima (RC) contributed to
464 conceptualisation, funding acquisition, methodology, and writing – review & editing; Myra
465 Spiliopoulou (MSp) contributed to funding acquisition, data curation, formal analysis, and
466 writing – review & editing; Susanne Staudinger (SStau) contributed to conceptualisation,
467 project administration, investigation, and writing – review & editing; Carsten Vogel (CV)
468 contributed to investigation, methodology, software, and writing – review & editing; Jorge
469 Simoes (JS), Uli Niemann (UN), Clara Puga (CP), Miro Schleicher (MSchl), Carlotta M.

470 Jarach (CMJ), Hafez Kader (HK), and Vishnu Unnikrishnan (VU) contributed to data
471 curation, formal analysis, methodology, and writing – review & editing; Benjamin Boecking
472 (BB) and Martin Schecklmann (MSche) contributed to conceptualisation, methodology,
473 investigation, and writing – review & editing; Christopher R. Cederroth (CRC) contributed to
474 funding acquisition, resources, and writing – review & editing; Steven C. Marcrum (SCM)
475 contributed to conceptualisation, investigation, and writing – review & editing; Patrick Neff
476 (PN) contributed to conceptualisation, methodology, and writing – review & editing;
477 Johannes Schobel (JS) contributed to investigation, software, and writing – review & editing;
478 Alberto Bernal-Robledano (ABR), Marta Martinez-Martinez (MMM), Nicolas Muller-
479 Locatelli (NML), Patricia Perez-Carpena (PPC), Paula Robles-Bolivar (PRB), Matthias Rose
480 (MR), Tabea Schiele (TS), Sam Denys (SD), Alba Escalera-Balsera (AEB), Alvaro Gallego-
481 Martinez (AGM), Leyre Hidalgo-Lopez (LHL), Nikos Markatos (NM), Juan Martin-Lagos
482 (JML), Sabine Stark (SSta), Alexandra Stege (AS), Evgenia Vassou (EV), Nicolas Verhaert
483 (NV), and Zoi Zachou (ZZ) contributed to investigation and writing – review & editing; Jan
484 Bulla (JB) and Beat Toedtli (BT) contributed to formal analysis, validation, and writing –
485 review & editing; Silvano Gallus (SG) contributed to funding acquisition and writing –
486 review & editing; Michael Koller (MK), Hazel Goedhart (HG) and Holger Crump (HC)
487 contributed to conceptualisation and writing – review & editing; and Alessandra Lugo (AL)
488 and Ilias Trochidis (IT) contributed to writing – review & editing.

489 All authors had full access to all the data in the study and had final responsibility for the
490 decision to submit for publication. SSch, WS, LB, and ME have directly accessed and verified
491 the underlying data reported in the manuscript.

492

493 **Funding**

494 This clinical trial received funding from the European Union’s Horizon 2020 Research and
495 Innovation Program (grant agreement number: 848261). The funders had no influence on trial

496 design and had no role in the collection, analysis, interpretation of the data, preparation of the
497 manuscript or in the decision to submit the manuscript for publication.

498

499 **Competing interests**

500 SSch received funding outside the present study from dtec.bw – Digitalization and
501 Technology Research Center of the Bundeswehr (MEXT project). dtec.bw is funded by the
502 European Union – NextGenerationEU. ME received research funding outside the present
503 study from the Rainwater Charitable Foundation and the Sonova Holding AG. BL received
504 consulting fees outside the present study from Schwabe Pharma AG, Neuromod, Sea Pharma,
505 and Rovi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript
506 writing or educational events outside the present study from Schwabe and Neuromod;
507 payment for expert testimony outside the present study from the Bavarian State; has an unpaid
508 leadership or fiduciary role outside the present study in the German Society for Brain
509 Stimulation in Psychiatry and the Tinnitus Research Initiative; owns stock or stock options
510 from Sea Pharma; and received equipment outside the present study from Neurocare and
511 Daymed. BM received support for attending meetings and/ or travel outside the present study
512 from the Charité – Universitätsmedizin Berlin. JALE received support for attending meetings
513 and conferences outside the present study from the University of Sydney. RC received
514 support for attending meetings and conferences outside the present study from the KU Leuven
515 University, Faculty of Psychology and Educational Sciences, Health Psychology, Belgium
516 and Adelante Center of Expertise in Rehabilitation and Audiology, The Netherlands. AEB
517 received research funding outside the present study from ibs.Granada/Fundación para la
518 Investigación Biosanitaria de Andalucía Oriental (FIBAO), European Molecular Biology
519 Organisation (EMBO) and Centro de Investigación Biomédica en Red Enfermedades Raras
520 (CIBERER). AGM received research funding outside the present study from the CECEU
521 2020, Andalusian Government of Spain (grant number: DOC_01677), and support for

522 attending meetings and/ or travel from the Andalusian Health Department (Grant number: PI-
523 0266-2021 – GEN4PHEN). PPC received research funding outside the present study from the
524 Consejería de Salud y Familias, Junta de Andalucía. 2020, Contrato Posdoctorales
525 Especialistas (RH-0150-2020), and the Instituto de Salud Carlos III., Bases neurofisiológicas
526 y perfil de seguridad de la terapia sonora en pacientes con acúfeno crónico severo
527 (PI22/01838). RP is a stakeholder of the Lenox uG. The Lenox uG also holds shares of the
528 HealthStudyClub GmbH. MSp received payment or honoraria for lectures, presentations,
529 speaker bureaus, manuscript writing or educational events outside the present study from
530 VAIA (Vlaamse AI Academie: <https://www.vaia.be/en/>), which is a collaboration between all
531 the universities and universities for applied sciences and arts in Flanders; payment effected by
532 KU Leuven. NV received research funding outside the present study from the Flanders
533 Research Foundation and VLAIO - KU Leuven, and has a planned patent with KU Leuven.
534 WS is a stakeholder of the Lenox uG. Lenox uG also holds shares of the HealthStudyClub
535 GmbH; received consulting fees outside the present study from Pansatori GmbH and Pohl-
536 Boskamp GmbH & Co. KG; received payment or honoraria for lectures, presentations,
537 speaker bureaus, manuscript writing or educational events outside the present study from
538 Schwabe Pharma AG and Medical Tribune; has a patent planned, issued or pending
539 (US20120046713A1).

540

541 **Ethical approval**

542 The study was approved by local ethics committees of Granada, Athens, Leuven, Regensburg
543 and Berlin (combined ethical approval for German sites).

544

545 **Data availability**

546 De-identified data generated from this trial will initially be available only on request for
547 researchers to reproduce results, later publicly via ZENODO. Current data availability will be
548 reported on the UNITI website (<https://uniti.tinnitusresearch.net/>).

549

550

551 **Acknowledgments**

552 We would like to thank all patients who participated in this trial, without whom this research
553 would not have been possible. We would like to further thank the whole consortium of the
554 UNITI-project for their feedback and support. Moreover, we would like to thank Simon
555 Grund for his support regarding the `mitml` R package.

556

557 **References**

- 558 1. De Ridder, D. *et al.* Tinnitus and tinnitus disorder: Theoretical and operational definitions
559 (an international multidisciplinary proposal). *Prog. Brain Res.* **260**, 1–25 (2021).
- 560 2. Jarach, C. M. *et al.* Global Prevalence and Incidence of Tinnitus: A Systematic Review
561 and Meta-analysis. *JAMA Neurol.* **79**, 888–900 (2022).
- 562 3. Baguley, D., McFerran, D. & Hall, D. Tinnitus. *The Lancet* **382**, 1600–1607 (2013).
- 563 4. Roberts, L. E. *et al.* Ringing Ears: The Neuroscience of Tinnitus. *J. Neurosci.* **30**, 14972–
564 14979 (2010).
- 565 5. Vanneste, S. & De Ridder, D. The auditory and non-auditory brain areas involved in
566 tinnitus. An emergent property of multiple parallel overlapping subnetworks. *Front. Syst.*
567 *Neurosci.* **6**, 31 (2012).
- 568 6. Sanchez, T. G., Valim, C. C. A. & Schlee, W. Long-lasting total remission of tinnitus: A
569 systematic collection of cases. *Prog. Brain Res.* **260**, 269–282 (2021).

- 570 7. Mazurek, B. *et al.* S3 Guideline: Chronic Tinnitus: German Society for
571 Otorhinolaryngology, Head and Neck Surgery e. V. (DGHNO-KHC). *HNO* **70**, 795–827
572 (2022).
- 573 8. Cima, R. F. F. *et al.* A multidisciplinary European guideline for tinnitus: diagnostics,
574 assessment, and treatment. *HNO* (2019) doi:10.1007/s00106-019-0633-7.
- 575 9. Bauer, C. A., Berry, J. L. & Brozoski, T. J. The effect of tinnitus retraining therapy on
576 chronic tinnitus: A controlled trial: A Controlled Trial of Tinnitus Retraining Therapy.
577 *Laryngoscope Investig. Otolaryngol.* **2**, 166–177 (2017).
- 578 10. Cima, R. F. *et al.* Specialised treatment based on cognitive behaviour therapy versus usual
579 care for tinnitus: a randomised controlled trial. *The Lancet* **379**, 1951–1959 (2012).
- 580 11. Henry, J. A. *et al.* Tinnitus Management: Randomized Controlled Trial Comparing
581 Extended-Wear Hearing Aids, Conventional Hearing Aids, and Combination Instruments.
582 *J. Am. Acad. Audiol.* **28**, 546–561 (2017).
- 583 12. Jastreboff, P. J. 25 Years of tinnitus retraining therapy. *HNO* **63**, 307–311 (2015).
- 584 13. Tunkel, D. E. *et al.* Clinical practice guideline: tinnitus executive summary. *Otolaryngol.-*
585 *-Head Neck Surg. Off. J. Am. Acad. Otolaryngol.-Head Neck Surg.* **151**, 533–541 (2014).
- 586 14. Kikidis, D. *et al.* Methodological Aspects of Randomized Controlled Trials for Tinnitus:
587 A Systematic Review and How a Decision Support System Could Overcome Barriers. *J.*
588 *Clin. Med.* **10**, 1737 (2021).
- 589 15. Schlee, W. *et al.* Towards a unification of treatments and interventions for tinnitus
590 patients: The EU research and innovation action UNITI. *Prog. Brain Res.* **260**, 441–451
591 (2021).
- 592 16. Schoisswohl, S. *et al.* Unification of Treatments and Interventions for Tinnitus Patients
593 (UNITI): a study protocol for a multi-center randomized clinical trial. *Trials* **22**, 875
594 (2021).

- 595 17. Simoes, J. P. *et al.* The statistical analysis plan for the unification of treatments and
596 interventions for tinnitus patients randomized clinical trial (UNITI-RCT). *Trials* **24**, 472
597 (2023).
- 598 18. Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: Updated
599 guidelines for reporting parallel group randomised trials. *J. Pharmacol. Pharmacother.* **1**,
600 100–107 (2010).
- 601 19. Newman, C. W., Jacobson, G. P. & Spitzer, J. B. Development of the Tinnitus Handicap
602 Inventory. *Arch. Otolaryngol. Head Neck Surg.* **122**, 143–148 (1996).
- 603 20. Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening
604 tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* **53**, 695–699 (2005).
- 605 21. Cima, R. F. F. Bothering tinnitus: Cognitive behavioral perspectives. *HNO* **66**, 369–
606 374 (2018).
- 607 22. Keidser, G., Dillon, H., Flax, M., Ching, T. & Brewer, S. The NAL-NL2 Prescription
608 Procedure. *Audiol. Res.* **1**, (2011).
- 609 23. Vogel, C., Schobel, J., Schlee, W., Engelke, M. & Pryss, R. UNITI Mobile-EMI-Apps for
610 a Large-Scale European Study on Tinnitus. *Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.*
611 *IEEE Eng. Med. Biol. Soc. Annu. Int. Conf.* **2021**, 2358–2362 (2021).
- 612 24. Genitsaridi, E. *et al.* Standardised profiling for tinnitus research: The European School for
613 Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-SQ). *Hear. Res.* **377**,
614 353–359 (2019).
- 615 25. Meikle, M. *et al.* The Tinnitus Functional Index: Development of a New Clinical Measure
616 for Chronic, Intrusive Tinnitus. *Ear Hear.* **33**, 153–76 (2011).
- 617 26. Hiller, W. & Goebel, G. Rapid assessment of tinnitus-related psychological distress using
618 the Mini-TQ. *Int. J. Audiol.* **43**, 600–604 (2004).
- 619 27. Kroenke, K. & Spitzer, R. L. The PHQ-9: A New Depression Diagnostic and Severity
620 Measure. *Psychiatr. Ann.* **32**, 509–515 (2002).

- 621 28. Harper, A., Power, M. & WHOQOL Group, X. Development of the World Health
622 Organization WHOQOL-Bref quality of life assessment. *Psychol. Med.* 551–558 (1998).
- 623 29. Landgrebe, M. *et al.* The Tinnitus Research Initiative (TRI) database: A new approach for
624 delineation of tinnitus subtypes and generation of predictors for treatment outcome. *BMC*
625 *Med. Inform. Decis. Mak.* **10**, (2010).
- 626 30. Adamchic, I. *et al.* Linking the Tinnitus Questionnaire and the subjective Clinical Global
627 Impression: Which differences are clinically important? *Health Qual. Life Outcomes* **10**,
628 79 (2012).
- 629 31. Fuller, T. *et al.* Cognitive behavioural therapy for tinnitus. *Cochrane Database Syst. Rev.*
630 **1**, CD012614 (2020).
- 631 32. Quartagno, M., Grund, S. & Carpenter, J. jomo: A Flexible Package for Two-level Joint
632 Modelling Multiple Imputation. *R J.* **11**, 205–228 (2019).
- 633 33. Grund, S., Robitzsch, A. & Luedtke, O. mitml: Tools for Multiple Imputation in
634 Multilevel Modeling. (2023).
- 635 34. Simões, J. *et al.* *The Statistical Analysis Plan for the Unification of Treatments and*
636 *Interventions for Tinnitus Patients Randomized Clinical Trial (UNITI-RCT)*. (2022).
637 doi:10.21203/rs.3.rs-2123725/v1.
- 638 35. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models
639 Using **lme4**. *J. Stat. Softw.* **67**, (2015).
- 640 36. Lenth, R. V. *et al.* emmeans: Estimated Marginal Means, aka Least-Squares Means.
641 (2023).
- 642 37. Searchfield, G. D. & Sanders, P. J. A randomized single-blind controlled trial of a
643 prototype digital polytherapeutic for tinnitus. *Front. Neurol.* **13**, (2022).
- 644 38. Kikidis, D., Vassou, E., Markatos, N., Schlee, W. & Iliadou, E. Hearing Aid Fitting in
645 Tinnitus: A Scoping Review of Methodological Aspects and Effect on Tinnitus Distress
646 and Perception. *J. Clin. Med.* **10**, 2896 (2021).

- 647 39. Sereda, M., Xia, J., El Refaie, A., Hall, D. A. & Hoare, D. J. Sound therapy (using
648 amplification devices and/or sound generators) for tinnitus. *Cochrane Database Syst. Rev.*
649 **12**, CD013094 (2018).
- 650 40. Meyerowitz-Katz, G. *et al.* Rates of Attrition and Dropout in App-Based Interventions for
651 Chronic Disease: Systematic Review and Meta-Analysis. *J. Med. Internet Res.* **22**, e20283
652 (2020).
- 653 41. Conlon, B. *et al.* Different bimodal neuromodulation settings reduce tinnitus symptoms in
654 a large randomized trial. *Sci. Rep.* **12**, 10845 (2022).
- 655